Association between transforming growth factor-b and hypertension

作者：Lijnen PJ^*; Petrov VV; Fagard RH

来源：American Journal of Hypertension, 2003, 16(7): 604-611.

DOI：10.1016/S0895-7061(03)00847-1

• transforming growth factor-b(1)
• blood pressure
• angiotensin II blockade
• polymorphism
• rats
• humans

Discordant findings are reported on the left ventricular transforming growth factor-beta(1) (TGF-beta(1)) mRNA levels in various rat models. Left ventricular TGF-beta(1) mRNA levels did not differ between spontaneously hypertensive rats (SHR) and normal rats, between deoxycorticosterone (DOCA)-salt and sham-operated hypertensive rats, but were increased in stroke-prone spontaneously hypertensive rats (SHRSP) and in post-myocardial infarction (MI) rats. Renal cortical TGF-beta(1) mRNA levels were, however, higher in DOCA-salt hypertensive rats.
Angiotensin II subtype I receptor antagonism (AT(1)R) and angiotensin converting enzyme inhibition (ACEI) decreased left ventricular and vascular smooth muscle TGF-beta(1) mRNA levels in SHR and renal TGF-beta(1) mRNA in DOCA-salt hypertensive rats and in SHRSP. In post-MI rats ventricular TGF-beta(1) mRNA decreased by AT(1)R antagonism.
In essential hypertensive patients, TGF-beta(1) protein as well as TGF-beta(1), mRNA levels are hyperexpressed. The TGF-beta(1) overproduction in hypertension can be attributed to various factors such as elevated angiotensin II, increased systemic blood pressure (BP) per se, increased fluid shear stress and a differential expression of TGF-beta(1) linked to DNA polymorphism in the promoter. The Arg(25) polymorphism in the TGF-beta(1) gene is associated with higher BP. A higher plasma TGF-beta(1) concentration is found in hypertensive patients with microalburninuria and left ventricle hypertrophy. In these patients, AT,R antagonism and ACEI reduced these plasma TGF-beta(1) levels significantly.

• 出版日期2003-7